• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

FDA Safety Database Analysis Identifies Delayed Postmarketing Events for Eculizumab in NMOSD

by
November 14, 2026
in Health
Reading Time: 6 mins read
0
FDA Safety Database Analysis Identifies Delayed Postmarketing Events for Eculizumab in NMOSD

FDA Safety Database Analysis Identifies Delayed Postmarketing Events for Eculizumab in NMOSD

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A retrospective pharmacovigilance evaluation examining the United States Food and Drug Administration Adverse Event Reporting System has characterized the real-world safety profile of eculizumab when prescribed for neuromyelitis optica spectrum disorder, identifying twenty-seven positive disproportionality signals alongside significant temporal heterogeneity in event reporting. Analyzing spontaneous reports submitted between the first quarter of 2004 and the first quarter of 2026, researchers isolated 954 deduplicated cases where the terminal complement inhibitor served as the primary suspect drug. Within this postmarketing cohort, the safety signals centered largely on general systemic symptoms, nervous system complaints, and musculoskeletal conditions, including fatigue, headache, pain, musculoskeletal stiffness, and dizziness. Notably, among the subset of cases providing verified timing records, half of the documented adverse events emerged more than 360 days after therapy initiation, establishing a median time to onset of 356 days. The findings provide longitudinal safety evidence to guide clinical risk surveillance across both initial administration and extended maintenance phases.

Neuromyelitis optica spectrum disorder represents a rare, highly disabling autoimmune inflammatory disease targeting the central nervous system, characterized predominantly by recurrent episodes of optic neuritis and longitudinally extensive transverse myelitis. Pathophysiologically, the condition is driven largely by pathogenic immunoglobulin G antibodies directed against the astrocytic water channel aquaporin-4. The binding of these autoantibodies initiates the classical complement cascade, cleaving complement component C5 into the proinflammatory anaphylatoxin C5a and C5b, which coordinates the assembly of the cytolytic membrane attack complex. This complement activation triggers severe astrocytic necrosis accompanied by bystander damage to nearby oligodendrocytes and neuronal axons. Eculizumab, a humanized monoclonal antibody, binds with high affinity to complement component C5, selectively preventing its cleavage and subsequent membrane attack complex assembly. While clinical trials demonstrated that terminal complement blockade substantially lowers relapse rates in adults with aquaporin-4 antibody-positive disease, systematic surveillance remains essential to delineate long-term real-world safety patterns.

To capture postmarketing outcomes beyond the circumscribed cohorts and rigid protocols of pre-approval clinical studies, the investigators extracted data from multiple relational files within the spontaneous reporting database, encompassing patient demographics, drug administration records, therapeutic indications, and reported adverse reactions. Case extraction deployed both the generic designation eculizumab and the proprietary brand name Soliris. Specificity for neuromyelitis optica spectrum disorder was established by cross-referencing diagnostic indications in the database files, thereby filtering out records related to other licensed uses such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis. Furthermore, the screening protocol strictly restricted inclusion to reports categorizing eculizumab as the primary suspect agent, deliberately excluding entries where the monoclonal antibody was assigned secondary suspect or concomitant status. Standard deduplication rules recommended by regulatory authorities were implemented using unique case identification numbers and receipt dates, preserving only the most recently updated version of each distinct patient case for statistical synthesis.

Signal detection and safety evaluations were conducted across two standardized hierarchical tiers of the Medical Dictionary for Regulatory Activities, evaluating system organ classes and discrete preferred terms. To mitigate false-positive associations arising from stochastic variation in low-frequency events, preferred terms required documentation in at least three individual case reports to qualify for formal screening. Disproportionality was quantified through the concurrent application of two established pharmacovigilance algorithms: the frequentist reporting odds ratio and the Bayesian confidence propagation neural network, which calculates the information component. A statistically robust signal demanded that the lower limit of the 95 percent confidence interval for the reporting odds ratio exceed one, while the lower bound of the 95 percent credibility interval for the information component remained strictly above zero. Identified signals then underwent semi-quantitative clinical prioritization scoring based on European Medicines Agency classifications of important medical events and designated medical events, integrating reporting ratios, algorithmic consistency, mortality proportions, and clinical severity.

The demographic distribution of the 954 eligible postmarketing reports mirrored known epidemiological characteristics of the target patient population, displaying a heavy female predominance comprising 845 individuals, or 88.6 percent of the analyzed cases, compared to 109 male patients, representing 11.4 percent. Among cases containing documented patient age, individuals aged 65 to 85 years represented the single largest group at 279 reports, or 29.2 percent, whereas 611 entries lacked complete age details. Geographically, reporting was concentrated within North America, with the United States generating 797 reports, accounting for 83.5 percent of the dataset, followed by Canada and Japan with 33 reports each, Germany with 21 reports, and broader European Union sources contributing 16 cases. Spontaneous submissions originated predominantly from consumers, who accounted for 548 reports or 57.4 percent, while physicians submitted 185 reports and other healthcare professionals provided 92 combined entries. Annual case volumes increased progressively over the study window, culminating in a peak of 293 reports during 2024.

At the overarching system organ class level, general disorders and administration site conditions formed the most frequently documented category with 497 entries, closely followed by nervous system disorders with 457 reports and musculoskeletal and connective tissue disorders with 293 cases. In terms of disproportionality strength, elevated reporting odds ratios emerged across social circumstances and surgical or medical procedures, displaying ratios of 5.66 and 4.63 alongside positive information components of 1.71 and 1.56, respectively. Musculoskeletal and connective tissue disorders demonstrated consistent statistical enrichment, registering a reporting odds ratio of 2.35 and an information component of 0.89. Additional positive signal trends manifested across nervous system disorders, which exhibited an odds ratio of 1.35 and an information component of 0.30, eye disorders with a ratio of 1.30, and skin and subcutaneous tissue disorders with a ratio of 1.29. Documented patient outcomes highlighted substantial clinical severity across the cohort, with other serious medical outcomes recorded in 709 cases, inpatient hospitalizations documented in 192 reports, and patient mortality recorded in 45 cases.

Granular evaluation at the preferred term level confirmed twenty-seven distinct adverse events satisfying both statistical disproportionality criteria. The highest absolute case counts occurred for systemic and neurological symptoms, led by fatigue with 93 reports, headache with 78 reports, and generalized pain with 56 reports, each exhibiting clear reporting enrichment relative to the broader database background. Musculoskeletal complaints featured prominent signal strengths, including pain in extremity across 39 cases, back pain across 32 reports, and musculoskeletal stiffness across 27 cases. Neurological events meeting detection thresholds included dizziness documented in 33 patients and paresthesia recorded in 24 reports. Independent clinical prioritization categorized twelve of the twenty-seven preferred term signals as possessing moderate clinical priority, driven primarily by ongoing functional morbidity and impact on quality of life linked to fatigue, musculoskeletal stiffness, back pain, limb discomfort, and dizziness. Significantly, no individual safety signal fulfilled the empirical criteria required for classification as a strong or high clinical priority.

Because terminal complement inhibition inherently impairs serum bactericidal activity against encapsulated pathogens, the investigators conducted dedicated surveillance of infectious complications. Overall, 208 case reports, representing 21.8 percent of the study population, documented adverse reactions categorized under the infections and infestations system organ class. The most frequent individual infectious diagnoses included urinary tract infection across 38 cases, COVID-19 and pneumonia with 18 cases each, sepsis in 14 patients, and nasopharyngitis across 13 reports. Serious life-threatening infections mechanistically associated with terminal complement deficiency were also documented, comprising four reports of meningitis, three cases of meningococcal meningitis, and three instances of meningococcal sepsis. However, when evaluated against database-wide reporting thresholds using both disproportionality metrics, no single infection-related preferred term generated a statistically positive signal. The authors emphasized that this statistical absence reflects low absolute counts and broad diagnostic term dispersion rather than diminished biological risk, noting that invasive meningococcal disease remains a critical known hazard requiring rigorous vaccination and vigilant clinical monitoring.

Temporal characteristics of adverse events were evaluated through dedicated time-to-onset analysis, restricted to the 152 reports that supplied both complete treatment initiation dates and validated event onset dates. Within this temporally documented subset, the median time from eculizumab initiation to the manifestation of the first adverse event was 356 days, with an interquartile range spanning from 78.50 days to 768.25 days. The distribution highlighted clear temporal bifurcation: while 16.45 percent of adverse events emerged rapidly within the initial 30 days of therapy and approximately 25 percent occurred within the first 90 days, fully 50.0 percent of reported events transpired beyond 360 days of continuous exposure. Comparative subgroup assessments between reports with and without complete dating confirmed comparable baseline demographics and similar proportional distributions of core adverse events, supporting the representativeness of the temporal subset while underscoring that safety surveillance protocols must span the entire duration of long-term biological therapy.

Interpreting the identified neurological and musculoskeletal signals requires careful differentiation between drug-attributable toxicity and clinical manifestations inherent to neuromyelitis optica spectrum disorder itself. Because the underlying neuroinflammatory disease inflicts structural damage upon optic pathways and spinal cord parenchyma, chronic symptoms such as neuropathic pain, paresthesias, spasticity, and visual impairment frequently persist as permanent sequelae from preceding relapses. Similarly, secondary physical deconditioning, restricted joint mobility, and prolonged exposure to concomitant glucocorticoids or immunosuppressive therapies can induce myopathy, osteoporosis, and chronic back pain, mimicking or confounding reported drug signals. Clinical trial records from the pivotal PREVENT trial and its open-label extension previously recorded headache, back pain, dizziness, and fatigue among eculizumab recipients, yet distinguishing background disease activity from pharmacotherapy effects in spontaneous reporting environments remains challenging. Consequently, the observed statistical signals represent reporting associations that demand focused clinical corroboration rather than definitive proof of biological causation.

The study authors delineated several methodological constraints inherent to pharmacovigilance databases that contextualize these findings. As a passive, spontaneous surveillance tool, the database lacks precise denominators for total drug exposure and contains no untreated control cohorts, precluding the calculation of true incidence rates or absolute risks. Substantial missing clinical information, including lack of aquaporin-4 or myelin oligodendrocyte glycoprotein serostatus, disease severity scores, relapse histories, vaccination records, and concomitant medications, introduces unmeasured confounding. Furthermore, heavy reliance on United States consumer reporting and the availability of complete temporal data in only 15.9 percent of cases may introduce reporting and selection biases. Despite these constraints, the real-world evidence delineates the practical reporting landscape of eculizumab in neuromyelitis optica spectrum disorder, reinforcing the necessity of dual-phase clinical vigilance that combines early monitoring for acute reactions with sustained long-term assessments of functional musculoskeletal, neurological, and infectious health.

Subject of Research: Pharmacovigilance analysis of postmarketing adverse event reports for eculizumab in neuromyelitis optica spectrum disorder

Article Title: Postmarketing safety profile of eculizumab for neuromyelitis optica spectrum disorder: a disproportionality and time-to-onset analysis

Article References: Li, X., Cai, M., Shi, R., Zhang, Z., & Tan, S. (2026). Postmarketing safety profile of eculizumab for neuromyelitis optica spectrum disorder: a disproportionality and time-to-onset analysis. Frontiers in Neurology, 17, Article 1958018. https://doi.org/10.3389/fneur.2026.1958018

Image Credits: AI Generated

DOI: 10.3389/fneur.2026.1958018

Keywords: eculizumab, neuromyelitis optica spectrum disorder, FAERS database, pharmacovigilance, disproportionality analysis, reporting odds ratio, time to onset, complement C5 inhibitor, aquaporin-4, drug safety monitoring, fatigue, headache, musculoskeletal stiffness, meningococcal infection, adverse event reporting, postmarketing surveillance

News Source: Ophelia Keating. (November 13, 2026). FDA Safety Database Analysis Identifies Delayed Postmarketing Events for Eculizumab in NMOSD. Scienmag.

Tags: adverse event reportingaquaporin-4complement C5 inhibitordisproportionality analysisdrug safety monitoringeculizumabFAERS databasefatigueheadachemeningococcal infectionmusculoskeletal stiffnessneuromyelitis optica spectrum disorderPharmacovigilancepostmarketing surveillancereporting odds ratiotime to onset
Share12Tweet7Share2ShareShareShare1

Related Posts

Integrating Environmental Sectors Key to Pandemic Prevention in Southeast Asia

Integrating Environmental Sectors Key to Pandemic Prevention in Southeast Asia

November 19, 2026
Right Bronchial Artery Preservation Linked to Lower Pneumonia Risk

Right Bronchial Artery Preservation Linked to Lower Pneumonia Risk

November 19, 2026

German Multicenter Protocol Outlines Cross-Sectional Investigation of Glioblastoma Suicidality

November 19, 2026

Stem Cell Factor MCP-1 Promotes Bone Regeneration in Rat Calvarial Defects

November 19, 2026

POPULAR NEWS

  • Corncrake Flagship Status Does Not Guarantee Local Recognition in Rural Romania

    Corncrake Flagship Status Does Not Guarantee Local Recognition in Rural Romania

    29 shares
    Share 12 Tweet 7
  • Pre-Rollout Survey Finds Eighteen Percent HPV Vaccine Uptake Among Chinese College Women

    29 shares
    Share 12 Tweet 7
  • Military Physicians Issue Fewer Medical Exemptions as Decision Fatigue Mounts Across Workdays

    29 shares
    Share 12 Tweet 7
  • Counseling and Mobile App Increase Postpartum Modern Contraceptive Uptake in Jordan

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Integrating Environmental Sectors Key to Pandemic Prevention in Southeast Asia

Right Bronchial Artery Preservation Linked to Lower Pneumonia Risk

Simulated Beijing Land Policies Shift Ecosystem Service Balance Inward by 2035

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.